Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Pangaea Oncology, S.A. (PANG.MC)
Barcelona, ES
Pangaea Oncology, S.A. delivers essential medical services to cancer patients across Spain and other European Union countries. Its extensive offerings encompass advanced molecular diagnostics, which include mutation analysis in tumor tissue and blood, gene amplification and translocation testing, immunohistochemistry, and gene expression profiling. The company is also active in clinical trials and provides in vitro drug profiling, employing techniques like MTT proliferation assays, western blotting, colony formation, migration and invasion assays, and gene silencing. Furthermore, Pangaea operates a specialized Dx platform for validating companion diagnostic platforms, benchmarking them against commercial alternatives, and offering bespoke research and development services to other diagnostic firms. A key focus also involves biomarker discovery, aiming to pinpoint novel targets for targeted therapies in their pre-clinical stages. Established in 2006, Pangaea Oncology, S.A. is headquartered in Barcelona, Spain.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.94% | +0.00% | -3.66% | -4.24% | -7.60% | -8.67% | -8.67% | +7.48% | -15.96% | -36.80% | -36.80% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-02 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Diagnostics & Research: +7.9%+1.8% Q4'25: +13.8% (vs Q4'23)
-
EPS growth Medical - Diagnostics & Research: +30.8%-187.2% Q4'25: +57.3% (vs Q4'23)
-
FCF margin FCF growth · Medical - Diagnostics & Research: +32.2%-2.2% Q4'25: -18.8% (vs Q4'23)
-
EBIT margin Medical - Diagnostics & Research: +9.6%-25.7% Q4'25: -29.1% (vs Q4'23)
-
ROIC Medical - Diagnostics & Research: +5.2%-15.0% Q4'25: -29.3% (vs Q4'23)
-
Share dilution Medical - Diagnostics & Research: 0.0%+12.2% Q4'25: +13.2% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Diagnostics & Research: -0.13×-6.16× Q4'25: -1.96× (vs Q4'23)
| Metric |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. |
|---|---|---|---|---|---|
| Revenue |
8.00M
est: 10.80M (-25.9%)
|
14.27M
est: 13.80M (+3.4%)
|
14.52M
est: 16.40M (-11.4%)
|
18.40M
18.40M – 18.40M
+12.2% YoY
|
20.40M
20.40M – 20.40M
+10.9% YoY
|
| EBITDA |
-1.56M
est: -484.1K (-221.7%)
|
1.19M
est: -1.29M (+192.0%)
|
-945.7K
est: -1.53M (+38.3%)
|
-1.72M
-1.72M – -1.72M
-12.2% YoY
|
-1.91M
-1.91M – -1.91M
-10.9% YoY
|
| EBIT |
-3.37M
est: -3.71M (+9.2%)
|
-1.39M
est: -4.32M (+67.8%)
|
-3.73M
est: -5.14M (+27.5%)
|
-5.76M
-5.76M – -5.76M
-12.2% YoY
|
-6.39M
-6.39M – -6.39M
-10.9% YoY
|
| Net Income |
-4.66M
est: -608.6K (-665.1%)
|
-1.17M
est: -1.37M (+14.6%)
|
-3.60M
est: -2.73M (-31.7%)
|
-1.02M
-1.02M – -1.02M
+62.5% YoY
|
—
— – —
+100.0% YoY
|
| SGA |
9.35M
est: 4.79M (+95.0%)
|
4.18M
est: 6.19M (-32.5%)
|
4.60M
est: 7.35M (-37.4%)
|
8.25M
8.25M – 8.25M
+12.2% YoY
|
9.15M
9.15M – 9.15M
+10.9% YoY
|
| EPS |
-0.15
est: -0.02 (-650.0%)
|
-0.03
est: -0.04 (+15.0%)
|
-0.11
est: -0.08 (-37.5%)
|
-0.03
-0.03 – -0.03
+62.5% YoY
|
—
— – —
+100.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-26 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-25 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-19 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-18 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-15 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-14 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-13 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-12 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-07 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-05 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-04 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Alejandro Garcia Moncayo | Executive Director of Corporate & Chief Financial Officer | — | — |
| Alejandro Martinez | Chief Medical Officer & Medical Director at IOR (Hospital Universitari Dexeus) | — | — |
| Carmen Albiol | Head of Operations for IOR | — | female |
| Cristina Masferrer EMBA | Chief Business Officer | — | — |
| Javier Rivela-Rodriguez | Co-Founder, Chief Executive Officer & Director | — | male |
| Miguel Angel Molina | Executive Director of Research & Development and Member of Scientific Committee | — | — |
| Rafael Rosell Costa | Chief Scientific Officer, Director, President & Member of Scientific Committee | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for PANG.MC
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
